Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNavy General Hospital, Beijing
About this trial
This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed/refractory peripheral t-cell lymphomas.
Eligibility criteria
Qualifiers
Pathologically confirmed angioimmunoblastic T-cell lymphoma according World Health Organization (WHO) classification;
Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
Disqualifiers
Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;
Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;
Pregnant or lactating women
Trial design
Treatments tested in this trial
- Azacytidine plus CAOLD regimen
Treatment groups
52 Participants
are divided into 1 treatment groupSponsors and collaborators
Navy General Hospital, Beijing
Lead sponsor
Chinese PLA General Hospital
Collaborator
Source ClinicalTrials.gov